| Pair Name | Thymoquinone, Bortezomib | ||
| Phytochemical Name | Thymoquinone (PubChem CID: 10281 ) | ||
| Anticancer drug Name | Bortezomib (PubChem CID: 387447 ) | ||
| Structure of Phytochemical |
|
Download
2D
MOL
3D
MOL
|
|
| Structure of Anticancer Drug |
|
Download
2D
MOL
3D
MOL
|
|
| Pair Name | Thymoquinone, Bortezomib | |||
| Disease Info | [ICD-11: 2A85.5] | Mantle cell lymphoma | Investigative | |
| Biological Phenomena | Induction-->Apoptosis | |||
| Gene Regulation | Down-regulation | Expression | BCL2 | hsa596 |
| Up-regulation | Expression | CASP3 | hsa836 | |
| Down-regulation | Expression | CDH13 | hsa1012 | |
| Up-regulation | Expression | COL11A2 | hsa1302 | |
| Down-regulation | Expression | IL6 | hsa3569 | |
| Down-regulation | Expression | MKI67 | hsa4288 | |
| Down-regulation | Expression | RELA | hsa5970 | |
| Down-regulation | Expression | TNF | hsa7124 | |
| Down-regulation | Expression | VEGFA | hsa7422 | |
| In Vitro Model | U266B1 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0566 |
| NCI-H929 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_1600 | |
| KMS-11 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_2989 | |
| RPMI-8226 | Plasma cell myeloma | Homo sapiens (Human) | CVCL_0014 | |
| In Vivo Model | Five-week-old athymic nu/nu male Balb/c mice were implanted subcutaneously in the right flank with U266 cells (2×10⁶ cells/100 uL of PBS/Matrigel). | |||
| Result | Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-KappaB regulated gene products in multiple myeloma xenograft mouse model | |||
| No. | Title | Href |
|---|---|---|
| 1 | Thymoquinone overcomes chemoresistance and enhances the anticancer effects of bortezomib through abrogation of NF-κB regulated gene products in multiple myeloma xenograft mouse model. Oncotarget. 2014 Feb 15;5(3):634-48. doi: 10.18632/oncotarget.1596. | Click |
